Skip to main content
. 2016 Jun 16;1(9):e85904. doi: 10.1172/jci.insight.85904

Figure 3. CITED4 improves cardiac remodeling after ischemia/reperfusion injury.

Figure 3

(A) No change in infarct size at 24 hours after ischemia reperfusion injury (IRI) from transient ligation of the left anterior descending artery (LAD) as demonstrated by TTC staining. (B) Noninvasive assessment of ventricular function demonstrates substantial dysfunction at 24 hours after IRI that improves significantly over time in the iCITED4 transgenics but not controls. n ≥ 5 mice per group per time point for analysis. **P < 0.01. (C) Representative micrographs of cardiac sections stained with MTS demonstrating a reduction of fibrosis in iCITED4 transgenics 4 weeks after IRI. High-magnification inlays demonstrate area of fibrosis and myocyte loss. Scale bar: 200 μm. (D) Quantification of fibrosis as a percentage of the total area (Control: 11.9% ± 2.6%, iCITED4: 3.5% ± 1.2%, n = 5 per group). **P < 0.01. (E) Trend to reduced lung weights consistent with a decreased degree of heart failure in CITED4 expressing mice, †P = 0.06 by Student’s t test. (F) Improvement in mortality in iCITED4 transgenics as compared with controls; n = 13 (control), 11 (iCITED4) at the start of the experiment; P < 0.05 by Log-Rank parametric test. For all graphs: significance determined by the Student’s t test unless otherwise specified; *P < 0.05, **P < 0.01.